“…However, the emergence of CQ‐resistance in the 1960s paved the way for the development of artemisinin combination therapy (ACT), worldwide (Beteck, Smit, Haynes, & N’Da, 2014; Dondorp et al., 2010). Unfortunately, the development of resistance to ACTs in Southeast Asia along with the lack of effective vaccine has called for urgent efforts to enrich the chemical libraries with new scaffolds with potent anti‐plasmodial activities and low incidence of resistance (Aneja, Kumar, Jairajpuri, & Abid, 2016; Dondorp et al., 2009; Gobbi et al., 2016; Leang et al., 2015).…”